Compare Amphastar Pharmaceuticals Inc (AMPH) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.15. The key difference: Roundhill S&P 500 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XDTE | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $30.81 | $44.76 |
52-Week Low | $16.87 | $36.00 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
XDTE trades at $39.20, up 0.44% today, but technical indicators signal a bearish trend with resistance at $39. The ETF generates high income through weekly dividends, with recent payouts ranging from $0.09 to $0.26, but faces NAV erosion risks. News highlights its role in providing frequent distributions via covered call strategies on S&P 500 options.
Outlook is cautious due to technical weakness and fundamental risks from NAV declines despite high yields. Investors may value the tax-efficient weekly income, but must weigh sustainability concerns if market sentiment shifts negatively. The bearish technical setup suggests limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
